Capmatinib
Capmatinib
Definition
An orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Capmatinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.
Also known as 2-Fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide, CAPMATINIB, INC 280, INC-280, INC280, INCB 28060, INCB028060, INCB28060 — per NCIT
Also identified as
- ATC L01EP01 per RXNORM
- ATC L01EX17 per RXNORM
- NCIT NCIT:C90564 per NCIT
- SCTID 874907006 per RXNORM
- SCTID 876837000 per RXNORM
- UNII TY34L4F9OZ per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Non-small cell lung carcinoma | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Lungs | may treat a disease of this organ | DERIVED · CC BY 4.0 |
1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.